Thursday, 23 Jan 2020

You are here

EUSTAR Analysis Yields Predictors of Skin Improvement in Diffuse Systemic Sclerosis

Systemic sclerosis is one of the most challenging of rheumatic diseases, often complicated by significant morbidity and leads to irreversible disability in many cases. While new treatments aimed to target major organ damage develop, little success has been achieved in management of skin changes of diffuse cutaneous systemic sclerosis (dcSSc).

It is generally agreed upon that prevention of progression of  active skin fibrosis in dcSSc patients is one of the major treatment goals, though it's unclear which subgroups of dcSSc patients will likely show improvement under standard of care without use of significant immunosuppression.

A longitudinal analysis of a recent, large-scale, observational study on the European Scleroderma Trials And Research (EUSTAR) database was performed to identify the predictors for improvement of skin fibrosis in patients with dcSSc. Such findings may optimize the inclusion criteria for dcSSc clinical trials and help rationalize use of immunosuppressive therapy in clinical setting.

A total of 919 with dcSSc who fulfilled American College of Rheumatology 1980 classification criteria with mRSS ≥7 at the first visit (baseline) and available data for the modified Rodnan skin score (mRSS) at 12±2 months follow-up were evaluated. 218/919 (24%) patients showed skin improvement over 1-year follow-up.

The candidate predictors of skin improvement were identified as follows:
▸ Baseline mRSS
▸ Disease duration
▸ ANA positive
▸ Anti-Scl70 positive
▸ Tendon friction rubs
▸ Proteinuria
▸ Conduction blocks
▸ Abnormal diastolic function
▸ Fibrosis on chest X-ray
▸ DLCO ≥70%
▸ Joint contractures

The most significant predictor of skin improvement was baseline mRSS (p<0.001). Other significant predictors were absence of tendon friction rubs and negative Scl-70 antibodies.

A key message resulting from the study is the important role of baseline mRSS to predict either progression or regression of skin fibrosis. These data further support a lower baseline mRSS as inclusion criteria to optimise the ratio of progressors over regressors for recruitment into clinical trials.
 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Steroid-Sparing Effect of Tocilizumab in Refractory Takayasu Arteritis

A controlled clinical trial has shown that giving the IL-6 receptor antibody, tocilizumab (TCZ), to  patients with Takayasu arteritis (TAK) results in clinical efficacy and has a steroid sparing efffect.

TULIP2 - Anifrolumab Succeeds in Lupus

NEJM has published the results of the TULIP2 trial with anifrolumab, an alpha interferon blocker, in the treatment of systemic lupus erythematosus, showing significant improvement (over placebo) in multiple lupus outcome measures, including BICLA, SRI-4, CLASI and others.

Steroids Up the Risk of Organ Damage in SLE

Lancet Rheumatology has reported the results of a multicenter follow-up study of systemic lupus erythematosus (SLE) patients showing that organ damange is linked to glucocorticoid use, independent of clinical or serological disease activity.

Treatment of Statin-induced anti-HMGCR myopathy

Statin-induced myositis, often with anti-HMGCR autoantibodies can be difficult to manage, Arthritis Research & Therapy yhas published the experience of 55 patient with HMGCR myopathy, demonstrating that while steroid management may be reasonable in select patients, the use of triple steroid/IVIG/SSI was very efficacious in induction.

Best of 2019 - 2019 EULAR Guidelines on Antiphospholipid Syndrome Management

A EULAR task force has reviewed the medical literature and developed evidence-based recommendations for the management of antiphospholipid syndrome (APS) in adults. They note that a high-risk antiphospholipid antibody (aPL) profile is associated with greater risk for thrombotic and obstetric APS.